Sunshine Biopharma Inc. (SBFM)
| Bid | 1.36 |
| Market Cap | 5.13M |
| Revenue (ttm) | 34.87M |
| Net Income (ttm) | -5.13M |
| EPS (ttm) | -7.32 |
| PE Ratio (ttm) | -0.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.44 |
| Volume | 72,188 |
| Avg. Volume (20D) | 1,458,295 |
| Open | 1.34 |
| Previous Close | 1.35 |
| Day's Range | 1.34 - 1.43 |
| 52-Week Range | 1.17 - 23.20 |
| Beta | 0.38 |
About SBFM
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast c...
Full Company ProfileAnalyst Forecast
According to 1 analyst ratings, the average rating for SBFM stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 963.83% from the latest price.
Stock Forecasts
3 weeks ago · accessnewswire.com
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingFORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
4 weeks ago · accessnewswire.com
Sunshine Biopharma Announces Positive Results of mRNA Therapy for CancerFORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a pharmaceutical company offering and researching life-saving medicines in a...
1 month ago · accessnewswire.com
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearFORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
